Data for the study was collected in 2 main centres for STIs, which together account for about 80% of STI diagnoses in the Lombardy region in Italy [1]. Both centres limited their access but stayed open during the lockdown that started on 8 March 2020 in Italy. The total attendance of the centres decreased by 70% from 1,696 patients in 2019 to 534 in 2020. In 2019, 86% of patients were male compared with 76% male in 2020. The prevalence of men who have sex with men (MSM) was 31% in 2019 and 35% in 2020. The median age was 37 years in 2019 and 33 in 2020.
In 2019, 233 confirmed STI cases were diagnosed. In the same period in 2020, 147 persons were diagnosed with STIs, a drop of 37%. Yet, this drop was noticed in the non-acute cases, such as genital warts and Molluscum, whereas the number of acute bacterial infections associated with MSM increased: in 2020, more cases of secondary syphilis, gonorrhoea, and M. genitalium were diagnosed.
The authors concluded that the COVID-19 pandemic, despite lockdown and advice on social/physical distancing, did not inhibit risky behaviours and that acute STIs even increased. “It was assumed that the lockdown would reduce the opportunity for sexual encounters and STIs. However, I was surprised by the number of new acute infections diagnosed in this short period of time. Gonorrhoea and syphilis are typically more prevalent in people in their 30s, so infections may have increased because the concentration of COVID-19 morbidity and mortality in the elderly made the younger, more active, cohort feel protected and so less risk-averse,” concluded Dr Marco Cusini (Policlinico of Milan, Italy).
Although it is unrealistic to prevent people from having sex, close contact during sexual intercourse inevitably involves an increased risk of SARS-CoV-2 infection. Dr Cusini concluded that these findings highlight the importance of ongoing screening for STIs and the importance of having these types of services open and available during pandemic restrictions.
- Cusini M, et al. COVID-19 and STIs. P1534, EADV 2020 Virtual Congress, 29-31 Oct.
Posted on
Previous Article
« Real-world data on brodalumab affirms efficacy and fast onset of action Next Article
Metastatic-melanoma immunotherapy may be tied to increase in second cancers »
« Real-world data on brodalumab affirms efficacy and fast onset of action Next Article
Metastatic-melanoma immunotherapy may be tied to increase in second cancers »
Table of Contents: EADV 2020
Featured articles
Late-Breaking News
Selective IL-23 blocker shows potential in psoriasis treatment
Promising results with nanobody treatment in psoriasis
Light at the end of the tunnel for chronic hand eczema
Epidermolysis bullosa: Novel wound treatment on the horizon
Efficacious non-steroidal topical for psoriasis
Oral JAK 1 inhibitor leads to fast itch relieve and remarkable skin clearance in AD
COVID-19: What Dermatologists Need to Know
Biologic psoriasis treatment and COVID-19 risk: Contradictory results
Much to be learned about COVID-19 and the skin
JAK Inhibitors – A Fascinating Novel Drug Class
JAK inhibitors in AA: re-establishing the immune privilege of hair follicles
JAK1 inhibition successful in hidradenitis suppurativa
Topical JAK inhibition: a novel treatment option for patients with mild-to-moderate AD
Urticaria – What’s new
Chronic inducible urticaria can require some detective work
Chronic spontaneous urticaria: hives, wheals & biomarkers
Ligelizumab for chronic spontaneous urticaria: a new star on the horizon
Infectious Diseases: Novel Developments
Bacterial resistance in skin infections – a challenging threat
Borreliosis: A multifaceted disease
Scabies – A global health challenge
Upcoming Treatments
Meaningful sleep improvement with IL-13 inhibition
Preventing foot odour with zinc oxide coated socks
Baricitinib in AD: Efficacy paired with consistent long-term results
Best of the Posters
Real-world data on brodalumab affirms efficacy and fast onset of action
Heightened risk for psychiatric comorbidities in hidradenitis suppurativa patients
Effects IL-13 blocker improves with longer treatment duration
Related Articles
December 17, 2020
Borreliosis: A multifaceted disease
December 17, 2020
Much to be learned about COVID-19 and the skin
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com